CD33-targeted therapies

CD33-targeted therapies are treatments designed to target a specific protein called CD33, which is commonly found on the surface of certain blood cells, including those involved in blood cancers like acute myeloid leukemia (AML). These therapies typically use substances like antibodies or drug-conjugates to recognize and bind to CD33, marking the cancer cells for destruction by the immune system or directly delivering toxic agents to them. By focusing on CD33, these treatments aim to selectively eliminate cancer cells while minimizing harm to healthy cells, potentially improving outcomes for patients with specific types of blood cancers.